STAAR Surgical to Report Third Quarter Results on October 30, 2024

Rhea-AI Summary

STAAR Surgical (NASDAQ: STAA) has announced it will release its third quarter 2024 financial results on Wednesday, October 30, 2024, after market close. The company will host an earnings webcast at 4:30 p.m. ET to discuss financial results and operational progress. STAAR Surgical specializes in ophthalmic surgery, designing and manufacturing implantable lenses including the EVO ICL™ product line. The company has sold over 3,000,000 ICLs and markets these lenses in more than 75 countries.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close.

Event: STAAR Surgical 3Q 2024 Financial Results Webcast
Date: Wednesday, October 30, 2024
Time: 4:30 p.m. ET / 1:30 p.m. PT
Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB

STAAR will also host an earnings webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. The live webcast, including an option to pre-register, can be accessed using the preceding link or the “Investors” section of the STAAR website at https://investors.staar.com/

A replay of the webcast will be available on October 30, 2024, at approximately 8:00 p.m. Eastern at the preceding link for at least 90 days.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241023428313/en/

Investors & Media

Brian Moore

Vice President, Investor Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Investors – Asia

Niko Liu, CFA

Director, Investor Relations and Corporate Development – Asia

+852-6092-5076

nliu@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical (STAA) release Q3 2024 earnings?

STAAR Surgical will release its third quarter 2024 financial results on Wednesday, October 30, 2024, after the market close.

What time is STAAR Surgical's (STAA) Q3 2024 earnings webcast?

STAAR Surgical's earnings webcast will be held on Wednesday, October 30, 2024, at 4:30 p.m. ET / 1:30 p.m. PT.

How many ICL lenses has STAAR Surgical (STAA) sold to date?

STAAR Surgical has sold more than 3,000,000 ICLs (Implantable Collamer Lenses) to date.

In how many countries does STAAR Surgical (STAA) market its ICL lenses?

STAAR Surgical markets its ICL lenses in over 75 countries.